<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618187</url>
  </required_header>
  <id_info>
    <org_study_id>SERES-101</org_study_id>
    <nct_id>NCT02618187</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis</brief_title>
  <official_title>A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seres Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seres Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287
      in Subjects with Mild-to-Moderate Ulcerative Colitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b multicenter, randomized, double-blind, placebo-controlled multiple dose
      study designed to evaluate the safety and tolerability of SER-287, and to evaluate the
      microbiome alterations and pharmacodynamics associated with two dosing regimens of SER-287 in
      adult subjects with active mild-to-moderate ulcerative colitis (UC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2016</start_date>
  <completion_date type="Actual">January 26, 2018</completion_date>
  <primary_completion_date type="Actual">December 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of SER-287</measure>
    <time_frame>Day 246</time_frame>
    <description>Treatment-Emergent Adverse Events Incidence by Treatment, System Organ Class and Preferred Term. The treatment period with SER-287 was eight weeks. All AEs were collected from the date of Informed Consent (up to 17 days of Screening) through Day 92 of the study. All SAEs were collected from the date of Informed Consent through Day 246 of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composition of the Intestinal Microbiome</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Changes in the composition of the microbiome were characterized by whole metagenomic sequencing (WMS) of subjects' stool samples. Changes in the composition of the microbiome were measured by quantifying the number of unique types of spore-forming bacteria detected in subjects' stool samples after eight weeks of induction treatment versus baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Engraftment of SER-287 Bacteria in All Treatment Arms</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The stool microbiomes of SERES-101 subjects, before and after treatment with SER-287, were characterized using whole metagenomic sequencing (WMS). SER-287 drug product was also characterized using WMS. Microbiome engraftment was assessed by the number of spore-forming species in the drug product lots that were also detected in subjects' post-treatment fecal samples but not detected at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission</measure>
    <time_frame>8 weeks</time_frame>
    <description>Defined as a Total Modified Mayo Score &lt;= 2 and an endoscopic subscore &lt;= 1.
The Total Modified Mayo Score is a measure of UC disease activity which ranges from 0 to 12 points and consists of four subscores (stool frequency, rectal bleeding, endoscopy, and physician global assessment), each graded from 0 to 3, with higher scores indicating more severe disease. The four components are summed together for a composite score, with a higher overall score indicating more severe disease (0 = no disease; 12 = worst disease). The Modified Mayo endoscopic subscore excludes friability from an endoscopic subscore of 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Improvement</measure>
    <time_frame>8 weeks</time_frame>
    <description>Defined as a decrease in endoscopic subscore &gt;= 1</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Weekly SER-287, after Placebo Pre-Treat.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily placebo, after Placebo Pre-Treat.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pre-treatment, followed by once daily placebo for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily SER-287, after Vanco. Pre-Treat.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weekly SER-287, after Vanco. Pre-Treat.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER-287</intervention_name>
    <arm_group_label>Daily SER-287, after Vanco. Pre-Treat.</arm_group_label>
    <arm_group_label>Weekly SER-287, after Placebo Pre-Treat.</arm_group_label>
    <arm_group_label>Weekly SER-287, after Vanco. Pre-Treat.</arm_group_label>
    <other_name>Eubacterial Spores, Purified Suspension, Encapsulated</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Daily placebo, after Placebo Pre-Treat.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Pre-Treat</intervention_name>
    <arm_group_label>Daily placebo, after Placebo Pre-Treat.</arm_group_label>
    <arm_group_label>Weekly SER-287, after Placebo Pre-Treat.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin Pre-Treat</intervention_name>
    <arm_group_label>Daily SER-287, after Vanco. Pre-Treat.</arm_group_label>
    <arm_group_label>Weekly SER-287, after Vanco. Pre-Treat.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ulcerative colitis diagnosed by routine clinical, radiographic, endoscopic and
             pathologic criteria (preferably confirmed by colonoscopy and pathology records within
             last 2 years or if unavailable, will need approval by medical monitor) Active
             mild-moderate UC as determined by sigmoidoscopy within approximately 3 days of
             randomization to study

        Exclusion Criteria:

          1. Fever &gt; 38.3Â°C

          2. Known or suspected toxic megacolon and/or known small bowel ileus

          3. Known history of Crohn's disease

          4. Subjects with serum albumin &lt;2.5 g/dL at baseline

          5. CMV polymerase chain reaction (PCR) positive from blood plasma at screening

          6. Known stool studies positive for ova and/or parasites or stool culture within the 30
             days before enrollment

          7. Subjects on cyclosporine or triple immunosuppression, Triple immunosuppression will
             include any three of the following classes of drugs taken in combination: steroids
             (i.e., prednisone/budesonide/budesonide MMX), immunosuppressant (i.e.,
             methotrexate/azathioprine/6-mercaptopurine), and/or other immunosuppressant (i.e.,
             tacrolimus, cellcept).

          8. Biologic medication (infliximab/ adalimumab/ golimumab/
             certolizumab/vedolizumab/ustekinumab/natalizumab) use within 3 months prior to
             screening

          9. Known active malignancy except for basal cell skin cancer, squamous cell skin cancer

         10. Subjects with previous colectomy, ostomy, J-pouch, or previous intestinal surgery
             (excluding cholecystectomy, appendectomy)

         11. Subjects with known history of celiac disease or gluten enteropathy

         12. Subjects with Clostridium difficile positive stool at Screening Visit

         13. Antibiotic use within the prior 1 month before randomization

         14. Expected to receive antibiotics within 8 weeks of signing the Informed Consent Form
             (ICF) (i.e., for planned/anticipated procedure)

         15. Received an investigational drug within 1 month before study entry

         16. Received an investigational antibody or vaccine within 3 months before study entry

         17. Previously enrolled in a SER-109/SER-287 study

         18. Received an FMT within the last 6 months

         19. Subjects with anatomic or medical contraindications to flexible sigmoidoscopy,
             including but not necessarily limited to toxic megacolon, gastrointestinal (GI)
             fistulas, immediate post-operative status from abdominal surgery, severe coagulopathy,
             large or symptomatic abdominal aortic aneurysm, or any subject where study physician
             deems subject at significant risk of complications of flexible sigmoidoscopy

         20. Unable to stop steroid enemas or suppositories or mesalamine enemas or suppositories
             before screening visit

         21. Unable to stop opiate treatment unless on a stable dose and no increase in dose
             planned for the duration of the study

         22. Unable to stop probiotics before screening visit

         23. Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for
             active malignancy (subjects on maintenance chemotherapy may only be enrolled after
             consultation with medical monitor)

         24. Known allergy or intolerance to oral vancomycin

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Community Clinical Research Network</name>
      <address>
        <city>Marlborough</city>
        <state>Massachusetts</state>
        <zip>01752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <results_first_submitted>September 25, 2018</results_first_submitted>
  <results_first_submitted_qc>March 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 20, 2019</results_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02618187/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: SERES-101 SAP</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02618187/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: SERES-101 Microbiome SAP</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02618187/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Weekly SER-287, After Placebo Pre-Treat.</title>
          <description>Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Placebo Pre-Treat</description>
        </group>
        <group group_id="P2">
          <title>Daily Placebo, After Placebo Pre-Treat.</title>
          <description>Placebo pre-treatment, followed by once daily placebo for 8 weeks
Placebo
Placebo Pre-Treat</description>
        </group>
        <group group_id="P3">
          <title>Daily SER-287, After Vanco. Pre-Treat.</title>
          <description>Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
        </group>
        <group group_id="P4">
          <title>Weekly SER-287, After Vanco. Pre-Treat.</title>
          <description>Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Weekly SER-287, After Placebo Pre-Treat.</title>
          <description>Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Placebo Pre-Treat</description>
        </group>
        <group group_id="B2">
          <title>Daily Placebo, After Placebo Pre-Treat.</title>
          <description>Placebo pre-treatment, followed by once daily placebo for 8 weeks
Placebo
Placebo Pre-Treat</description>
        </group>
        <group group_id="B3">
          <title>Daily SER-287, After Vanco. Pre-Treat.</title>
          <description>Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
        </group>
        <group group_id="B4">
          <title>Weekly SER-287, After Vanco. Pre-Treat.</title>
          <description>Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" spread="16.12"/>
                    <measurement group_id="B2" value="45.8" spread="15.20"/>
                    <measurement group_id="B3" value="47.8" spread="18.59"/>
                    <measurement group_id="B4" value="47.9" spread="11.18"/>
                    <measurement group_id="B5" value="47.1" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other - Indian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montreal Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Ulcerative Proctitis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Left-sided UC (distal UC)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extensive UC (pancolitis)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severity of UC</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Receiving UC Treatment Prior to or On Date of First Pre-treatment Dose</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since First UC Diagnosis</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149.1" spread="141.34"/>
                    <measurement group_id="B2" value="138.2" spread="85.91"/>
                    <measurement group_id="B3" value="152.9" spread="143.77"/>
                    <measurement group_id="B4" value="142.1" spread="105.41"/>
                    <measurement group_id="B5" value="146.0" spread="120.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of SER-287</title>
        <description>Treatment-Emergent Adverse Events Incidence by Treatment, System Organ Class and Preferred Term. The treatment period with SER-287 was eight weeks. All AEs were collected from the date of Informed Consent (up to 17 days of Screening) through Day 92 of the study. All SAEs were collected from the date of Informed Consent through Day 246 of the study.</description>
        <time_frame>Day 246</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Weekly SER-287, After Placebo Pre-Treat.</title>
            <description>Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Placebo Pre-Treat</description>
          </group>
          <group group_id="O2">
            <title>Daily Placebo, After Placebo Pre-Treat.</title>
            <description>Placebo pre-treatment, followed by once daily placebo for 8 weeks
Placebo
Placebo Pre-Treat</description>
          </group>
          <group group_id="O3">
            <title>Daily SER-287, After Vanco. Pre-Treat.</title>
            <description>Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
          </group>
          <group group_id="O4">
            <title>Weekly SER-287, After Vanco. Pre-Treat.</title>
            <description>Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of SER-287</title>
          <description>Treatment-Emergent Adverse Events Incidence by Treatment, System Organ Class and Preferred Term. The treatment period with SER-287 was eight weeks. All AEs were collected from the date of Informed Consent (up to 17 days of Screening) through Day 92 of the study. All SAEs were collected from the date of Informed Consent through Day 246 of the study.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gastrointestinal disorders (GI) - total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Abdominal distension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Abdominal pain upper</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Abnormal faeces</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Bowel movement irregularity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Colitis ulcerative (worsening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Diarrhoea haemorrhagic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Dyspepsia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Faecal incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Flatulence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Frequent bowel movements</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Gastrooesophageal reflux disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Mucous stools</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Oesophagitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Rectal discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI-Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders &amp; administration site conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, poisoning and procedural complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive system and breast disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, thoracic and mediastinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composition of the Intestinal Microbiome</title>
        <description>Changes in the composition of the microbiome were characterized by whole metagenomic sequencing (WMS) of subjects' stool samples. Changes in the composition of the microbiome were measured by quantifying the number of unique types of spore-forming bacteria detected in subjects' stool samples after eight weeks of induction treatment versus baseline.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Sensitivity Analysis Population - 1 (all randomized subjects with an evaluable stool sample collected at baseline and one evaluable stool sample collected at Visit 12 or Early Termination (ET) visit collected within a 2 week window surrounding Visit 12)</population>
        <group_list>
          <group group_id="O1">
            <title>Weekly SER-287, After Placebo Pre-Treat.</title>
            <description>Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Placebo Pre-Treat</description>
          </group>
          <group group_id="O2">
            <title>Daily Placebo, After Placebo Pre-Treat.</title>
            <description>Placebo pre-treatment, followed by once daily placebo for 8 weeks
Placebo
Placebo Pre-Treat</description>
          </group>
          <group group_id="O3">
            <title>Daily SER-287, After Vanco. Pre-Treat.</title>
            <description>Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
          </group>
          <group group_id="O4">
            <title>Weekly SER-287, After Vanco. Pre-Treat.</title>
            <description>Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
          </group>
        </group_list>
        <measure>
          <title>Composition of the Intestinal Microbiome</title>
          <description>Changes in the composition of the microbiome were characterized by whole metagenomic sequencing (WMS) of subjects' stool samples. Changes in the composition of the microbiome were measured by quantifying the number of unique types of spore-forming bacteria detected in subjects' stool samples after eight weeks of induction treatment versus baseline.</description>
          <population>Sensitivity Analysis Population - 1 (all randomized subjects with an evaluable stool sample collected at baseline and one evaluable stool sample collected at Visit 12 or Early Termination (ET) visit collected within a 2 week window surrounding Visit 12)</population>
          <units>Richness of spore-forming species</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.333" spread="8.588"/>
                    <measurement group_id="O2" value="0.167" spread="9.475"/>
                    <measurement group_id="O3" value="12.1" spread="9.871"/>
                    <measurement group_id="O4" value="5.615" spread="9.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: the two groups compared show no difference in mean ranks Alternative hypothesis: the two groups compared show a difference in mean ranks</non_inferiority_desc>
            <p_value>0.766</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2-sided</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: the two groups compared show no difference in mean ranks Alternative hypothesis: the two groups compared show a difference in mean ranks</non_inferiority_desc>
            <p_value>0.037</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2-sided</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: the two groups compared show no difference in mean ranks Alternative hypothesis: the two groups compared show a difference in mean ranks</non_inferiority_desc>
            <p_value>0.313</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2-sided</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: the two groups compared show no difference in mean ranks Alternative hypothesis: the two groups compared show a difference in mean ranks</non_inferiority_desc>
            <p_value>0.384</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2-sided</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: the two groups compared show no difference in mean ranks Alternative hypothesis: the two groups compared show a difference in mean ranks</non_inferiority_desc>
            <p_value>0.237</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>2-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Engraftment of SER-287 Bacteria in All Treatment Arms</title>
        <description>The stool microbiomes of SERES-101 subjects, before and after treatment with SER-287, were characterized using whole metagenomic sequencing (WMS). SER-287 drug product was also characterized using WMS. Microbiome engraftment was assessed by the number of spore-forming species in the drug product lots that were also detected in subjects' post-treatment fecal samples but not detected at baseline.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Sensitivity Analysis Population - 1 (all randomized subjects with an evaluable stool sample collected at baseline and one evaluable stool sample collected at Visit 12 or Early Termination (ET) visit collected within a two-week window surrounding Visit 12)</population>
        <group_list>
          <group group_id="O1">
            <title>Weekly SER-287, After Placebo Pre-Treat.</title>
            <description>Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Placebo Pre-Treat</description>
          </group>
          <group group_id="O2">
            <title>Daily Placebo, After Placebo Pre-Treat.</title>
            <description>Placebo pre-treatment, followed by once daily placebo for 8 weeks
Placebo
Placebo Pre-Treat</description>
          </group>
          <group group_id="O3">
            <title>Daily SER-287, After Vanco. Pre-Treat.</title>
            <description>Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
          </group>
          <group group_id="O4">
            <title>Weekly SER-287, After Vanco. Pre-Treat.</title>
            <description>Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment of SER-287 Bacteria in All Treatment Arms</title>
          <description>The stool microbiomes of SERES-101 subjects, before and after treatment with SER-287, were characterized using whole metagenomic sequencing (WMS). SER-287 drug product was also characterized using WMS. Microbiome engraftment was assessed by the number of spore-forming species in the drug product lots that were also detected in subjects' post-treatment fecal samples but not detected at baseline.</description>
          <population>Sensitivity Analysis Population - 1 (all randomized subjects with an evaluable stool sample collected at baseline and one evaluable stool sample collected at Visit 12 or Early Termination (ET) visit collected within a two-week window surrounding Visit 12)</population>
          <units>Richness SER-287 spore-forming species</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.222" spread="5.974"/>
                    <measurement group_id="O2" value="4.333" spread="1.862"/>
                    <measurement group_id="O3" value="16.7" spread="7.469"/>
                    <measurement group_id="O4" value="13.615" spread="6.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Weekly SER-287, after Placebo Pre-Treat. tested against Daily placebo, after Placebo Pre-Treat., for superiority</non_inferiority_desc>
            <p_value>0.257</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>1-sided</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Daily SER-287, After Vanco. Pre-Treat. tested against Daily Placebo, After Placebo Pre-Treat., for superiority</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>1-sided</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Weekly SER-287, After Vanco. Pre-Treat. tested against Daily Placebo, After Placebo Pre-Treat., for superiority</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>1-sided</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Weekly SER-287, After Vanco. Pre-Treat. tested against Weekly SER-287, After Placebo Pre-Treat., for superiority</non_inferiority_desc>
            <p_value>0.009</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>1-sided</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Daily SER-287, After Vanco. Pre-Treat., tested against Weekly SER-287, After Vanco. Pre-Treat., for superiority</non_inferiority_desc>
            <p_value>0.168</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>1-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Remission</title>
        <description>Defined as a Total Modified Mayo Score &lt;= 2 and an endoscopic subscore &lt;= 1.
The Total Modified Mayo Score is a measure of UC disease activity which ranges from 0 to 12 points and consists of four subscores (stool frequency, rectal bleeding, endoscopy, and physician global assessment), each graded from 0 to 3, with higher scores indicating more severe disease. The four components are summed together for a composite score, with a higher overall score indicating more severe disease (0 = no disease; 12 = worst disease). The Modified Mayo endoscopic subscore excludes friability from an endoscopic subscore of 1.</description>
        <time_frame>8 weeks</time_frame>
        <population>ITT, where the following were counted as missing: missing post-treatment endoscopy; adding UC medication for a flare during the treatment period; early termination prior to Day 48</population>
        <group_list>
          <group group_id="O1">
            <title>Weekly SER-287, After Placebo Pre-Treat.</title>
            <description>Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Placebo Pre-Treat</description>
          </group>
          <group group_id="O2">
            <title>Daily Placebo, After Placebo Pre-Treat.</title>
            <description>Placebo pre-treatment, followed by once daily placebo for 8 weeks
Placebo
Placebo Pre-Treat</description>
          </group>
          <group group_id="O3">
            <title>Daily SER-287, After Vanco. Pre-Treat.</title>
            <description>Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
          </group>
          <group group_id="O4">
            <title>Weekly SER-287, After Vanco. Pre-Treat.</title>
            <description>Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Remission</title>
          <description>Defined as a Total Modified Mayo Score &lt;= 2 and an endoscopic subscore &lt;= 1.
The Total Modified Mayo Score is a measure of UC disease activity which ranges from 0 to 12 points and consists of four subscores (stool frequency, rectal bleeding, endoscopy, and physician global assessment), each graded from 0 to 3, with higher scores indicating more severe disease. The four components are summed together for a composite score, with a higher overall score indicating more severe disease (0 = no disease; 12 = worst disease). The Modified Mayo endoscopic subscore excludes friability from an endoscopic subscore of 1.</description>
          <population>ITT, where the following were counted as missing: missing post-treatment endoscopy; adding UC medication for a flare during the treatment period; early termination prior to Day 48</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4923</p_value>
            <method>Fisher Exact</method>
            <param_type>Rate difference (SER-287 - placebo)</param_type>
            <param_value>13.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.87</ci_lower_limit>
            <ci_upper_limit>30.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0237</p_value>
            <method>Fisher Exact</method>
            <param_type>Rate difference (SER-287 - placebo)</param_type>
            <param_value>40.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.21</ci_lower_limit>
            <ci_upper_limit>64.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2579</p_value>
            <method>Fisher Exact</method>
            <param_type>Rate difference (SER-287 - placebo)</param_type>
            <param_value>17.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>35.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endoscopic Improvement</title>
        <description>Defined as a decrease in endoscopic subscore &gt;= 1</description>
        <time_frame>8 weeks</time_frame>
        <population>ITT, where the following were counted as missing: missing post-treatment endoscopy; adding UC medication for a flare during the treatment period; early termination prior to Day 48</population>
        <group_list>
          <group group_id="O1">
            <title>Weekly SER-287, After Placebo Pre-Treat.</title>
            <description>Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Placebo Pre-Treat</description>
          </group>
          <group group_id="O2">
            <title>Daily Placebo, After Placebo Pre-Treat.</title>
            <description>Placebo pre-treatment, followed by once daily placebo for 8 weeks
Placebo
Placebo Pre-Treat</description>
          </group>
          <group group_id="O3">
            <title>Daily SER-287, After Vanco. Pre-Treat.</title>
            <description>Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
          </group>
          <group group_id="O4">
            <title>Weekly SER-287, After Vanco. Pre-Treat.</title>
            <description>Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Improvement</title>
          <description>Defined as a decrease in endoscopic subscore &gt;= 1</description>
          <population>ITT, where the following were counted as missing: missing post-treatment endoscopy; adding UC medication for a flare during the treatment period; early termination prior to Day 48</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1973</p_value>
            <method>Fisher Exact</method>
            <param_type>Rate difference (SER-287 - placebo)</param_type>
            <param_value>24.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.04</ci_lower_limit>
            <ci_upper_limit>53.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1783</p_value>
            <method>Fisher Exact</method>
            <param_type>Rate difference (SER-287 - placebo)</param_type>
            <param_value>30.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>60.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6195</p_value>
            <method>Fisher Exact</method>
            <param_type>Rate difference (SER-287 - placebo)</param_type>
            <param_value>14.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.93</ci_lower_limit>
            <ci_upper_limit>40.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 246</time_frame>
      <desc>All AEs were collected from the date of Informed Consent (up to 17 days of Screening) through Day 92 of the study. All SAEs were collected from the date of Informed Consent through Day 246 of the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Weekly SER-287, After Placebo Pre-Treat.</title>
          <description>Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Placebo Pre-Treat</description>
        </group>
        <group group_id="E2">
          <title>Daily Placebo, After Placebo Pre-Treat.</title>
          <description>Placebo pre-treatment, followed by once daily placebo for 8 weeks
Placebo
Placebo Pre-Treat</description>
        </group>
        <group group_id="E3">
          <title>Daily SER-287, After Vanco. Pre-Treat.</title>
          <description>Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
        </group>
        <group group_id="E4">
          <title>Weekly SER-287, After Vanco. Pre-Treat.</title>
          <description>Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
Eubacterial Spores, Purified Suspension, Encapsulated
Vancomycin Pre-Treat</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening depression</sub_title>
                <description>The one case of worsening depression was reported as moderate severity, and probably not or likely not related to study drug, as determined by the investigator.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Treatment-emergent adverse event</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Treatment-emergent adverse event</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Treatment-emergent adverse event</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <description>Treatment-emergent adverse event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Treatment-emergent adverse event</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <description>Treatment-emergent adverse event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Treatment-emergent adverse event</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Treatment-emergent adverse event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Proposed publications must be submitted to Sponsor for review at least 30 days prior to publication. Sponsor can require removal of confidential information other than study data and Site/Investigator agree to consider Sponsorâs suggestions with respect to the presentation of study data. Sponsor can force publication to be deferred for a period of up to 60 days in order to file any patents.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michele Trucksis, Chief Medical Officer</name_or_title>
      <organization>Seres Therapeutics</organization>
      <phone>617-945-9626</phone>
      <email>mtrucksis@serestherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

